Last reviewed · How we verify
Camrelizumab and Cetuximab
Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy.
Camrelizumab blocks PD-1 to enhance immune response while cetuximab blocks EGFR to inhibit tumor cell growth, combining immunotherapy with targeted therapy. Used for Head and neck squamous cell carcinoma (Phase 3), Nasopharyngeal carcinoma (Phase 3).
At a glance
| Generic name | Camrelizumab and Cetuximab |
|---|---|
| Sponsor | Yue He, MD |
| Drug class | PD-1 inhibitor + EGFR inhibitor combination |
| Target | PD-1 and EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab is a PD-1 inhibitor that releases immune checkpoint inhibition, allowing T cells to attack tumor cells. Cetuximab is an EGFR-targeting monoclonal antibody that blocks growth signaling and antibody-dependent cellular cytotoxicity. The combination leverages both immune activation and direct anti-tumor mechanisms.
Approved indications
- Head and neck squamous cell carcinoma (Phase 3)
- Nasopharyngeal carcinoma (Phase 3)
Common side effects
- Infusion-related reactions
- Immune-related adverse events (irAEs)
- Rash/acneiform dermatitis
- Diarrhea
- Fatigue
Key clinical trials
- Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE3)
- Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (PHASE2)
- Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer (PHASE2)
- Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab and Cetuximab CI brief — competitive landscape report
- Camrelizumab and Cetuximab updates RSS · CI watch RSS
- Yue He, MD portfolio CI